1. Disease Information

1.1 Definition and overview

B‑lymphoblastic leukemia/lymphoma (B‑ALL/LBL) is a precursor B‑cell neoplasm characterized by proliferation of lymphoblasts in bone marrow/blood (leukemia) and/or mass lesions (lymphoma). Contemporary classifications emphasize that recurrent genetic abnormalities define biologically and clinically meaningful subtypes that drive risk stratification and, in select cases, targeted therapy. This framing is explicit in both the ICC and recent WHO-aligned summaries emphasizing that childhood B‑ALL is “characterised by recurrent genetic abnormalities that drive risk‑directed treatment strategies.” (ryan2023wholegenomesequencing pages 1-2).

1.2 Classification context (WHO‑HAEM5 and ICC)

The ICC article on ALL/LBL (peer‑reviewed; Nov 2023; URL https://doi.org/10.1007/s00428-022-03448-8) outlines multiple recurrent genetic B‑ALL entities and explicitly subdivides BCR::ABL1‑like (Ph‑like) ALL into mechanistically actionable categories (ABL‑class vs JAK‑STAT–activated vs NOS) with corresponding diagnostic requirements (duffield2023internationalconsensusclassification pages 3-4, duffield2023internationalconsensusclassification pages 4-6).

A WHO‑HAEM5‑aligned review notes that WHO‑HAEM5 upgraded some 2017 “provisional” entities (e.g., BCR::ABL1‑like, iAMP21) and added newer types such as ETV6::RUNX1‑like and a category of “B‑ALL with other defined genetic features,” and recommends use of “B‑ALL/LBL, not further classified” when comprehensive genomic testing is not feasible (kansal2023diagnosisandmolecular pages 5-7).

1.3 Synonyms / alternative names

Commonly used names in the literature include: - B‑ALL; B‑cell acute lymphoblastic leukemia - B‑LBL; B‑lymphoblastic lymphoma - B‑lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities (ICC/WHO framing) (duffield2023internationalconsensusclassification pages 4-6, kansal2023diagnosisandmolecular pages 5-7)

1.4 Key identifiers (ICD/MeSH/MONDO/Orphanet/OMIM)

Not determinable from the retrieved evidence set. The provided materials were not ontology/registry entries and did not list ICD‑10/11, MeSH, Orphanet, OMIM, or MONDO identifiers.

1.5 Evidence source type

The classification and mechanistic information here is derived from aggregated disease‑level resources (WHO/ICC‑aligned reviews and consensus classifications) and large cohort studies (e.g., WGS diagnostic validation; COG relapse analysis) rather than single‑patient EHR data (ryan2023wholegenomesequencing pages 1-2, rheingold2024determinantsofsurvival pages 2-3).

2. Etiology

2.1 Primary causal factors

The defining “causal factors” for this knowledge‑base entry are recurrent genetic alterations that initiate or sustain leukemogenesis (chromosomal aneuploidy, translocations/fusions, focal copy‑number changes, and subtype‑defining point mutations) (kansal2023diagnosisandmolecular pages 5-7, duffield2023internationalconsensusclassification pages 4-6, duffield2023internationalconsensusclassification pages 3-4).

2.2 Risk factors

Germline predisposition / inherited risk: In ICC, low hypodiploid B‑ALL is highlighted as frequently involving TP53 mutations, with an important clinical point that ~50% of pediatric TP53 mutations in this setting may be germline (Li‑Fraumeni syndrome implication) (duffield2023internationalconsensusclassification pages 3-4).

Age-related risk: Favorable genetic subtypes (high hyperdiploidy; ETV6::RUNX1) are common in childhood but become rare in older adults; an excerpt gives approximate distribution across age strata (kansal2023diagnosisandmolecular pages 7-8).

Environmental/infectious risk factors: Not supported by the retrieved evidence set.

2.3 Protective factors and gene–environment interactions

Not supported by the retrieved evidence set.

3. Phenotypes

3.1 Clinical presentation (general)

The retrieved evidence focuses on classification and diagnostics rather than detailed symptom prevalence. However, clinically relevant phenotypes documented include: - Bone marrow–dominant relapse and CNS relapse patterns in pediatric ALL: isolated bone marrow relapse 58.7%; any bone marrow involvement 72.5%; isolated CNS relapse 21.7%; overall CNS involvement 32.9% (COG analysis) (rheingold2024determinantsofsurvival pages 2-3).

3.2 Age of onset

Childhood B‑ALL is dominated by specific favorable genetic subtypes; in one WHO‑aligned summary, ~90% of childhood ALL is B‑ALL and favorable subtypes contribute a large proportion of standard‑risk disease (kansal2023diagnosisandmolecular pages 5-7, kansal2023diagnosisandmolecular pages 7-8).

3.3 Suggested HPO terms (high-level; limited by evidence)

Because symptom-level data were not extracted in the current evidence set, only broad, high-confidence phenotype terms are suggested: - Abnormality of the bone marrow (HP:0005560) - Leukemia (HP:0001909) - Central nervous system involvement (HP:0001310) — supported by CNS relapse frequency patterns (rheingold2024determinantsofsurvival pages 2-3)

4. Genetic / Molecular Information (core of this entity)

4.1 Current understanding: recurrent genetic subtypes

Modern WHO/ICC frameworks partition B‑ALL/LBL into multiple recurrent genetic subtypes; the ICC provides detailed diagnostic/prognostic notes for several recently recognized entities (DUX4‑r, ZNF384‑r, MEF2D‑r, NUTM1‑r, MYC‑r, CDX2/UBTF, HLF‑r), as well as single-gene mutant entities (PAX5 P80R; IKZF1 N159Y) (duffield2023internationalconsensusclassification pages 4-6, duffield2023internationalconsensusclassification pages 6-8).

A WHO‑aligned review highlights that WHO‑HAEM5 expanded the list beyond classic cytogenetic categories and that many new subtypes require advanced genomic methods (expression profiling, WGS, improved copy-number analysis) (kansal2023diagnosisandmolecular pages 5-7).

4.2 Subtype catalog (structured)

A structured table of major subtypes, frequencies (when available), prognosis notes, and detection methods is provided below.

Table: This table compacts the major recurrent genetic subtypes recognized in modern WHO-HAEM5/ICC-aligned B-lymphoblastic leukemia/lymphoma classification, using only the gathered evidence. It highlights subtype-defining lesions, age distribution, approximate frequencies, prognosis, and the molecular methods most useful for detection.

4.3 Key subtype-specific highlights (examples)

• BCR::ABL1‑like (Ph‑like) B‑ALL: ICC subdivides into ABL‑class rearranged vs JAK‑STAT–activated vs NOS; ABL‑class lesions are clinically important because they may respond to ABL1‑targeting TKIs (imatinib, dasatinib), and detection may use FISH and targeted transcriptome sequencing, but definitive assignment requires genetic studies including gene expression and fusion/mutation testing (duffield2023internationalconsensusclassification pages 3-4).
• DUX4‑rearranged B‑ALL: ICC notes excellent prognosis and technical pitfalls (IGH::DUX4 can be missed by targeted sequencing/FISH); diagnosis can rely on DUX4 RNA/protein overexpression or CD371 by flow cytometry (duffield2023internationalconsensusclassification pages 4-6). WHO‑aligned summary notes favorable outcome despite high MRD and association with ERG alterations/IKZF1 deletions; NGS (RNA or DNA) is typically required (kansal2023diagnosisandmolecular pages 15-16).
• Hypodiploid B‑ALL: ICC distinguishes near‑haploid from low hypodiploid and emphasizes masked hypodiploidy; low hypodiploidy associates with TP53 mutations (with germline implication) (duffield2023internationalconsensusclassification pages 3-4).

4.4 Molecular diagnostic yield (WGS as a comprehensive test)

Whole genome sequencing (WGS) in a 210‑patient childhood B‑ALL cohort detected 294 subtype‑defining genetic abnormalities in 96% (202/210) and showed concordance with standard-of-care methods and WTS, supporting WGS as a “standalone, reliable genetic test” for identifying subtype-defining abnormalities (Jan 2023; URL https://doi.org/10.1038/s41375-022-01806-8) (ryan2023wholegenomesequencing pages 1-2). A tightly cropped image of the paper’s subtype-frequency table is available (ryan2023wholegenomesequencing media 2101e72e).

5. Environmental Information

Not supported by the retrieved evidence set.

6. Mechanism / Pathophysiology

6.1 Conceptual model (current understanding)

Across subtypes, leukemogenesis generally follows a driver-lesion → altered transcription/signaling → aberrant B‑cell precursor differentiation/proliferation → clinical leukemia/lymphoma chain. ICC emphasizes pathway-based classes particularly for Ph‑like ALL, in which lesions activate ABL‑class kinase signaling or JAK‑STAT signaling, creating a rationale for targeted kinase inhibition (duffield2023internationalconsensusclassification pages 3-4).

6.2 Examples of subtype-linked mechanisms

• ABL‑class rearranged Ph‑like ALL: oncogenic ABL-family signaling; potential sensitivity to ABL1 TKIs (duffield2023internationalconsensusclassification pages 3-4).
• JAK‑STAT–activated Ph‑like ALL: lesions such as CRLF2 rearrangements, EPOR rearrangements, JAK fusions/mutations (duffield2023internationalconsensusclassification pages 3-4).
• IKZF1 N159Y: ICC notes abnormal nuclear localization and enhanced cell–cell adhesion phenotypes, consistent with a distinct biology compared with deletion-driven IKZF1 alterations (duffield2023internationalconsensusclassification pages 6-8).

6.3 Suggested ontology terms (high-level)

Because mechanistic detail in the retrieved evidence is subtype‑overview rather than pathway experiments, only broad mapping is suggested: - GO: B cell differentiation (GO:0030183) - GO: JAK‑STAT cascade (GO:0007259) (Ph‑like JAK‑STAT–activated group) (duffield2023internationalconsensusclassification pages 3-4) - GO: protein tyrosine kinase signaling pathway (GO:0007169) (ABL‑class group) (duffield2023internationalconsensusclassification pages 3-4) - CL: B cell (CL:0000236) - CL: B cell precursor (CL:0000816) (conceptual target cell)

7. Anatomical Structures Affected

7.1 Organ/tissue level

• Bone marrow is the principal disease compartment and the dominant site of relapse; in a large pediatric dataset, isolated bone marrow relapse accounted for 58.7%, and any bone marrow involvement for 72.5% (rheingold2024determinantsofsurvival pages 2-3).
• Central nervous system involvement is clinically important; isolated CNS relapse 21.7% and overall CNS involvement 32.9% at relapse in the same cohort (rheingold2024determinantsofsurvival pages 2-3).

7.2 Suggested UBERON terms

• Bone marrow: UBERON:0002371
• Central nervous system: UBERON:0001016

8. Temporal Development

8.1 Onset

The evidence set supports that favorable genetic subtypes are predominantly pediatric and may arise early (including prenatal initiation for ETV6::RUNX1 and high hyperdiploidy) (kansal2023diagnosisandmolecular pages 7-8).

8.2 Relapse timing patterns

In the COG analysis of 16,115 patients treated on 12 frontline trials, late relapse was common: ~50% of B‑ALL relapses occurred ≥36 months after diagnosis, and ~16% occurred >5 years (rheingold2024determinantsofsurvival pages 2-3). Relapse timing varies by subtype: ETV6::RUNX1 and trisomy 4+10 have later median time-to-relapse (~43 months), whereas hypodiploid and KMT2A‑rearranged relapse earlier (median ~12.5–18 months) (rheingold2024determinantsofsurvival pages 2-3).

9. Inheritance and Population

9.1 Population epidemiology

Incidence/prevalence estimates were not retrievable from the current evidence set.

9.2 Germline predisposition and inheritance

A clinically actionable inheritance-relevant point is the potential germline origin of TP53 mutations in low hypodiploid B‑ALL (Li‑Fraumeni syndrome context), highlighted by ICC (duffield2023internationalconsensusclassification pages 3-4).

10. Diagnostics

10.1 Diagnostic criteria and classification

The ICC emphasizes that accurate classification of B‑ALL with recurrent genetic abnormalities requires genetic studies, and some groups require gene-expression profiling (GEP) for assignment; CRLF2 rearrangement is one immunophenotypic clue for Ph‑like ALL but otherwise immunophenotypes may be non-distinctive (duffield2023internationalconsensusclassification pages 3-4, duffield2023internationalconsensusclassification pages 6-8).

10.2 Recommended testing modalities (current implementations)

Cytogenetics/FISH/RT‑PCR remain core for classic alterations, while RNA‑seq, WGS, and broader NGS increasingly enable complete assignment of emerging entities and “B‑other” cases (kansal2023diagnosisandmolecular pages 5-7, ryan2023wholegenomesequencing pages 1-2).

WGS in diagnostics: WGS can detect aneuploidies, structural variants, and focal copy-number changes and allocate many B‑other cases to emerging genomic groups; a WGS diagnostic feasibility study reported 100% concordance with standard-of-care and high yield for assigning emerging subgroups (concept supported in WHO‑aligned review; and WGS cohort data show 96% classification success) (ryan2023wholegenomesequencing pages 1-2, kansal2023diagnosisandmolecular pages 5-7).

10.3 Measurable residual disease (MRD)

The ELN 2024 adult ALL recommendations emphasize MRD’s central prognostic role and discuss standardization and validation initiatives for molecular/NGS-based MRD, including EuroClonality NGS standardization efforts and specific guidance for Ph+ ALL MRD by qRT‑PCR (Blood May 2024; URL https://doi.org/10.1182/blood.2023020794) (gokbuget2024diagnosisprognosticfactors pages 13-14).

In pediatric relapse analyses, MRD by COG flow cytometry had typical sensitivity 10−4, and end‑of‑induction MRD ≥0.01% was associated with increased relapse risk (p < 0.0001) (rheingold2024determinantsofsurvival pages 2-3).

10.4 Differential diagnosis

Not supported by the retrieved evidence set.

11. Outcome / Prognosis

11.1 Prognostic stratification by genetics

WHO/ICC-aligned summaries maintain classic prognostic groupings (favorable: high hyperdiploidy; ETV6::RUNX1; adverse: hypodiploidy; BCR::ABL1; KMT2A rearranged), while newly defined subtypes show distinct outcomes (e.g., DUX4‑r favorable; MEF2D‑r relatively poor) (kansal2023diagnosisandmolecular pages 5-7, duffield2023internationalconsensusclassification pages 4-6, kansal2023diagnosisandmolecular pages 15-16).

11.2 Post‑relapse survival and subtype-specific outcomes (pediatric)

A large COG analysis reported 2053 relapses among 16,115 pediatric patients (12.7%); the 5‑year OS post‑relapse was 48.9 ± 1.2% overall and 52.5 ± 1.3% for B‑ALL. The abstract also reports cytogenetic‑specific post‑relapse OS: ETV6::RUNX1 74.4 ± 3.1%, Trisomy 4+10 70.2 ± 3.6%, versus poor outcomes for hypodiploidy 14.2 ± 6.1%, KMT2A‑rearranged 31.9 ± 7.7%, and TCF3::PBX1 36.8 ± 6.6% (Sep 2024; URL https://doi.org/10.1038/s41375-024-02395-4) (rheingold2024determinantsofsurvival pages 2-3).

Direct abstract quote (COG relapse study): “The 5-year OS post-relapse for the entire cohort was 48.9 ± 1.2%; B-ALL:52.5 ± 1.3%…” and “Patients with hypodiploidy, KMT2A-rearrangement, and TCF3::PBX1 had short median time-to-relapse (12.5-18 months) and poor OS post-relapse (14.2 ± 6.1%, 31.9 ± 7.7%, 36.8 ± 6.6%).” (rheingold2024determinantsofsurvival pages 2-3).

12. Treatment

12.1 Current applications and real-world implementations (selected)

12.1.1 Blinatumomab (CD19×CD3 BiTE)

A 2024 pediatric immunotherapy review summarizes multiple use-cases and randomized relapse settings: - In early single-agent studies at RP2D, overall response rate 39%, and 52% of responders achieved MRD negativity (brivio2024nakedantibodiesand pages 3-4). - In randomized pediatric first marrow relapse settings, post‑reinduction blinatumomab improved 2‑year DFS 54.4% vs 39.0% versus chemotherapy and improved 2‑year EFS 66.2% vs 27.1% in high‑risk first relapse BCP‑ALL (brivio2024nakedantibodiesand pages 3-4). - For bone marrow relapses, blinatumomab produced superior 4‑year DFS/OS 72.7%/97.1% vs chemotherapy 53.7%/84.8%; outcomes were similarly poor for isolated extramedullary relapse (4‑year DFS ~36–39%) (brivio2024nakedantibodiesand pages 3-4).

Direct abstract quote (review): “With the novel therapeutic options introduced in the last years, including immunotherapies and targeted antibodies, the treatment of ALL is undergoing major changes.” (Haematologica May 2024 review; abstract statement) (brivio2024nakedantibodiesand pages 3-4).

12.1.2 Targeted therapy linkage (genotype → therapy)

ICC explicitly connects ABL‑class Ph‑like lesions (ABL1/ABL2/CSF1R/PDGFRB fusions) to potential responsiveness to ABL1-targeting TKIs and indicates that identifying these lesions is clinically actionable (duffield2023internationalconsensusclassification pages 3-4).

12.2 Treatment strategy and expert opinion (authoritative sources)

The ELN 2024 adult recommendations are an authoritative expert-panel source emphasizing that adult ALL management requires comprehensive biologic characterization and MRD-driven risk stratification, with MRD methodology standardization and genomic high-risk groups (e.g., Ph-like ALL, IKZF1 deletions) considered in risk assessment (gokbuget2024diagnosisprognosticfactors pages 13-14).

12.3 Suggested MAXO terms (high level)

• Chemotherapy (MAXO:0000058)
• Tyrosine kinase inhibitor therapy (for ABL‑class or BCR::ABL1‑positive disease) (duffield2023internationalconsensusclassification pages 3-4)
• Blinatumomab therapy / bispecific antibody therapy (MAXO term depends on local MAXO implementation) (brivio2024nakedantibodiesand pages 3-4)
• Measurable residual disease monitoring (diagnostic action; MAXO not always used for monitoring)

13. Prevention

Not supported by the retrieved evidence set.

14. Other Species / Natural Disease

Not supported by the retrieved evidence set.

15. Model Organisms

Not supported by the retrieved evidence set.

High-value, recent sources used (with dates and URLs)

• Duffield AS, Mullighan CG, Borowitz MJ. International consensus classification of acute lymphoblastic leukemia/lymphoma. Virchows Archiv. Nov 2023. https://doi.org/10.1007/s00428-022-03448-8 (duffield2023internationalconsensusclassification pages 4-6, duffield2023internationalconsensusclassification pages 3-4, duffield2023internationalconsensusclassification pages 6-8)
• Ryan S et al. Whole genome sequencing provides comprehensive genetic testing in childhood B‑cell acute lymphoblastic leukaemia. Leukemia. Jan 2023. https://doi.org/10.1038/s41375-022-01806-8 (ryan2023wholegenomesequencing pages 1-2, ryan2023wholegenomesequencing media 2101e72e)
• Gökbuget N et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations. Blood. May 2024. https://doi.org/10.1182/blood.2023020794 (gokbuget2024diagnosisprognosticfactors pages 13-14)
• Rheingold SR et al. Determinants of survival after first relapse of ALL: a COG study. Leukemia. Sep 2024. https://doi.org/10.1038/s41375-024-02395-4 (rheingold2024determinantsofsurvival pages 2-3)
• Brivio E et al. Naked antibodies and antibody‑drug conjugates: targeted therapy for childhood ALL. Haematologica. May 2024. https://doi.org/10.3324/haematol.2023.283815 (brivio2024nakedantibodiesand pages 3-4)

Limitations of this report (evidence gaps)

1) Standard ontology identifiers (MONDO/MeSH/ICD/Orphanet/OMIM) were not present in the retrieved sources. 2) Environmental risk factors, prevention strategies, and gene–environment interaction evidence were not retrieved. 3) Model organism and other-species data were not retrieved. 4) Several clinically important modern outcomes (e.g., adult frontline chemo‑immunotherapy, inotuzumab and CAR‑T quantitative outcomes, and population incidence/prevalence) require additional targeted retrieval beyond the present evidence set.

References

1. (ryan2023wholegenomesequencing pages 1-2): Sarra Ryan, John Peden, Zoya Kingsbury, Claire Schwab, Terena James, Petri Polonen, Martina Mijuskovic, Jennifer Becq, Richard Yim, Ruth Cranston, Dale Hedges, Kathryn Roberts, Charles Mullighan, Ajay Vora, Lisa Russell, Anthony Moorman, David Bentley, Christine Harrison, and Mark Ross. Whole genome sequencing provides comprehensive genetic testing in childhood b-cell acute lymphoblastic leukaemia. Leukemia, 37:518-528, Jan 2023. URL: https://doi.org/10.1038/s41375-022-01806-8, doi:10.1038/s41375-022-01806-8. This article has 89 citations and is from a highest quality peer-reviewed journal.

2. (duffield2023internationalconsensusclassification pages 3-4): Amy S. Duffield, Charles G. Mullighan, and Michael J. Borowitz. International consensus classification of acute lymphoblastic leukemia/lymphoma. Virchows Archiv, 482:11-26, Nov 2023. URL: https://doi.org/10.1007/s00428-022-03448-8, doi:10.1007/s00428-022-03448-8. This article has 226 citations and is from a peer-reviewed journal.

3. (duffield2023internationalconsensusclassification pages 4-6): Amy S. Duffield, Charles G. Mullighan, and Michael J. Borowitz. International consensus classification of acute lymphoblastic leukemia/lymphoma. Virchows Archiv, 482:11-26, Nov 2023. URL: https://doi.org/10.1007/s00428-022-03448-8, doi:10.1007/s00428-022-03448-8. This article has 226 citations and is from a peer-reviewed journal.

4. (kansal2023diagnosisandmolecular pages 5-7): Rina Kansal. Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts—part 2: b-/t-cell acute lymphoblastic leukemias. Lymphatics, 1:118-154, Jul 2023. URL: https://doi.org/10.3390/lymphatics1020011, doi:10.3390/lymphatics1020011. This article has 12 citations.

5. (rheingold2024determinantsofsurvival pages 2-3): Susan R. Rheingold, Deepa Bhojwani, Lingyun Ji, Xinxin Xu, Meenakshi Devidas, John A. Kairalla, Mary Shago, Nyla A. Heerema, Andrew J. Carroll, Heather Breidenbach, Michael Borowitz, Brent L. Wood, Anne L. Angiolillo, Barbara L. Asselin, W. Paul Bowman, Patrick Brown, ZoAnn E. Dreyer, Kimberly P. Dunsmore, Joanne M. Hilden, Eric Larsen, Kelly Maloney, Yousif Matloub, Leonard A. Mattano, Stuart S. Winter, Lia Gore, Naomi J. Winick, William L. Carroll, Stephen P. Hunger, Elizabeth A. Raetz, and Mignon L. Loh. Determinants of survival after first relapse of acute lymphoblastic leukemia: a children’s oncology group study. Leukemia, 38:2382-2394, Sep 2024. URL: https://doi.org/10.1038/s41375-024-02395-4, doi:10.1038/s41375-024-02395-4. This article has 81 citations and is from a highest quality peer-reviewed journal.

6. (kansal2023diagnosisandmolecular pages 7-8): Rina Kansal. Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts—part 2: b-/t-cell acute lymphoblastic leukemias. Lymphatics, 1:118-154, Jul 2023. URL: https://doi.org/10.3390/lymphatics1020011, doi:10.3390/lymphatics1020011. This article has 12 citations.

7. (duffield2023internationalconsensusclassification pages 6-8): Amy S. Duffield, Charles G. Mullighan, and Michael J. Borowitz. International consensus classification of acute lymphoblastic leukemia/lymphoma. Virchows Archiv, 482:11-26, Nov 2023. URL: https://doi.org/10.1007/s00428-022-03448-8, doi:10.1007/s00428-022-03448-8. This article has 226 citations and is from a peer-reviewed journal.

8. (mahdaoui2025areviewof pages 2-3): Chaimae EL MAHDAOUI, Hind Dehbi, and Siham Cherkaoui. A review of the latest updates in cytogenetic and molecular classification and emerging approaches in identifying abnormalities in acute lymphoblastic leukemia. Lymphatics, Aug 2025. URL: https://doi.org/10.3390/lymphatics3030023, doi:10.3390/lymphatics3030023. This article has 1 citations.

9. (kansal2023diagnosisandmolecular pages 15-16): Rina Kansal. Diagnosis and molecular pathology of lymphoblastic leukemias and lymphomas in the era of genomics and precision medicine: historical evolution and current concepts—part 2: b-/t-cell acute lymphoblastic leukemias. Lymphatics, 1:118-154, Jul 2023. URL: https://doi.org/10.3390/lymphatics1020011, doi:10.3390/lymphatics1020011. This article has 12 citations.

10. (ryan2023wholegenomesequencing media 2101e72e): Sarra Ryan, John Peden, Zoya Kingsbury, Claire Schwab, Terena James, Petri Polonen, Martina Mijuskovic, Jennifer Becq, Richard Yim, Ruth Cranston, Dale Hedges, Kathryn Roberts, Charles Mullighan, Ajay Vora, Lisa Russell, Anthony Moorman, David Bentley, Christine Harrison, and Mark Ross. Whole genome sequencing provides comprehensive genetic testing in childhood b-cell acute lymphoblastic leukaemia. Leukemia, 37:518-528, Jan 2023. URL: https://doi.org/10.1038/s41375-022-01806-8, doi:10.1038/s41375-022-01806-8. This article has 89 citations and is from a highest quality peer-reviewed journal.

11. (gokbuget2024diagnosisprognosticfactors pages 13-14): Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver Ottmann, Anita Rijneveld, Philippe Rousselot, Josep Ribera, and Renato Bassan. Diagnosis, prognostic factors, and assessment of all in adults: 2024 eln recommendations from a european expert panel. Blood, 143:1891-1902, May 2024. URL: https://doi.org/10.1182/blood.2023020794, doi:10.1182/blood.2023020794. This article has 99 citations and is from a highest quality peer-reviewed journal.

12. (brivio2024nakedantibodiesand pages 3-4): Erica Brivio, Francisco Bautista, and C. Michel Zwaan. Naked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia. Haematologica, 109:1700-1712, May 2024. URL: https://doi.org/10.3324/haematol.2023.283815, doi:10.3324/haematol.2023.283815. This article has 19 citations.